股票&市場分析
瀏覽 333萬
內容 5430
![](data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABgAAAAYCAYAAADgdz34AAAACXBIWXMAACE4AAAhOAFFljFgAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAD0SURBVHgB1ZVLDoIwEIan+FhzBLwBN9CufSSoe/UmchJ1bRQT2TfegCN4BFxLqK2JoTFI26kL/ZfD5PugM6QA/x6iazikbCOawrKEeD6hJ7BMo2B/ZoMWAVZVvOV01N+BRbymh+0CMuBwrSrl9pheFvAtQRTRnBRAXSTaGcgkCQt4WxwVgaCqmh2XkcBFYizASqwEGIm1wFaCEnyQ5Lc79FZi89Q+D/DJBVyF+X5X/SIHgXh7n3eef3j4qnEOcTSk2XsvZsi18NmYruv6bdfUCm4lwMCNBVi4kcAFLqPdIhe4ViAvHBe4VqBeOBi4ceQc4FfzANvOjGritIyVAAAAAElFTkSuQmCC)
Shares of China's CanSino Biologics rise as much as 15% on W...
Shares of China's CanSino Biologics rise as much as 15% on Wednesday afternoon.
Cansino and Aerogen are teaming up to develop and market an inhaled version of CanSino's recombinant COVID-19 shot Convidecia, which is already approved in China as a one-and-done injectable.
康希諾生物日內走高,一度漲超15%,此前宣佈與Aerogen合作開發全球首款吸入式新冠疫苗。
免責聲明:社區由Moomoo Technologies Inc.提供,僅用於教育目的。
更多信息
2